Table S1 Relevant image information for nonclinical sample sets. Table S2 Nonclinical tumor samples, key patient data.Table S3 Overview of data used for statistical analysis. Table S4 Validation of CD8 IA using CD8 single stain and CD8/PD-L1 dual stain. (DOCX 91Â kb
The correlation diagrams of CD8 + TIL, FOXP3 + TIL, and CD8/FOXP3 ratio with residual cancer burden ...
Table S1. Demographic and clinicopathologic characteristics of hepatocellular carcinoma samples in 2...
Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb
CD8/PD-L1 dual IHC, quality control; co-registration; details of the automated classification assess...
Figure S1 IA classification of CD8+ lymphocytes. Figure S2 IA classification of elongate CD8+ lympho...
Table S1. CD8 levels distribution according to tumor subtype and clinicopathological features. (DOCX...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Figure S1. Comparison of CD8 levels in PD-L1 negative and positive groups. A & B: Comparison of CD8 ...
Figure S2. Immunohistochemically staining of CD8 proteins in patients with hepatocellular carcinoma....
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
Figure S1 Digital image analysis segments CD8+ and PD-L1+ cells in dual-labelled sections of NSCLC. ...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...
Figure S1. Immunohistochemically staining of PD-L1 proteins in patients with hepatocellular carcinom...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...
Schematic representation of process for TIL initiation, expansion and testing. Figure S2. Lymphocyti...
The correlation diagrams of CD8 + TIL, FOXP3 + TIL, and CD8/FOXP3 ratio with residual cancer burden ...
Table S1. Demographic and clinicopathologic characteristics of hepatocellular carcinoma samples in 2...
Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb
CD8/PD-L1 dual IHC, quality control; co-registration; details of the automated classification assess...
Figure S1 IA classification of CD8+ lymphocytes. Figure S2 IA classification of elongate CD8+ lympho...
Table S1. CD8 levels distribution according to tumor subtype and clinicopathological features. (DOCX...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Figure S1. Comparison of CD8 levels in PD-L1 negative and positive groups. A & B: Comparison of CD8 ...
Figure S2. Immunohistochemically staining of CD8 proteins in patients with hepatocellular carcinoma....
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
Figure S1 Digital image analysis segments CD8+ and PD-L1+ cells in dual-labelled sections of NSCLC. ...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...
Figure S1. Immunohistochemically staining of PD-L1 proteins in patients with hepatocellular carcinom...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...
Schematic representation of process for TIL initiation, expansion and testing. Figure S2. Lymphocyti...
The correlation diagrams of CD8 + TIL, FOXP3 + TIL, and CD8/FOXP3 ratio with residual cancer burden ...
Table S1. Demographic and clinicopathologic characteristics of hepatocellular carcinoma samples in 2...
Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb